jump to navigation

MBBP’s Client Abpro Collaborating with MedImmune on Medical Advancement 12/01/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Corporate, Life Sciences, Medical Devices.
Tags: , , , , , , , , , , ,
add a comment

MBBP’s client Abpro, a pioneer in the field of industrial biochemistry, has recently entered into a Collaboration Agreement with MedImmune, the global biologics research and development arm of AstraZeneca. The collaboration will advance the development of a preclinical, novel bispecific antibody targeting angiopoietin-2 and vascular endothelial growth factor (Ang2-VEGF). Abpro will contribute its strong scientific, technical and clinical expertise to this partnership, along with its core technology platform, DiversImmuneTM, which will be utilized to further develop the bispecific antibody. Ian Chan, CEO and co-founder of Abpro, has expressed the Company’s enthusiasm towards collaborating with MedImmune, as the two businesses work together to advance these innovative therapeutics into the clinic.

For more information, read the full article.

MBBP Client Harvard Making Breakthroughs in Blood Stem Cell Research 11/21/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Life Sciences, Medical Devices.
Tags: , , , , , , , , , , , , ,
add a comment

Harvard University has recently completed a license agreement with Magenta Therapeutics, a newly launched start-up in Cambridge, Massachusetts, in order to continue research and development related to new approaches to blood stem cell transplantation. The deal will help transform this science from that of a “last resort” into safer, more effective therapy for patients who suffer from blood diseases, cancers, and immune disorders. The license agreement has given Magenta the opportunity to utilize a platform of technologies developed at Harvard, Massachusetts General Hospital (MGH), and Boston Children’s Hospital.

This revolutioHarvard Universitynary technology has been most recently advanced in the laboratory of David Scadden, the Gerald and Darlene Jordan Professor of Medicine and professor of stem cell and regenerative biology at Harvard, and director of the Center for Regenerative Medicine at MGH. Scadden’s lab has made advances in how donor cells are selected, harvested, and prepared for transplant, improving projected outcomes for patients. For more information, read the Harvard Gazette and Boston Business Journal articles.

 

Client Paragonix Technologies Enters Into Distribution Agreement with Pacific West Medical Sales for Paragonix SherpaPak™ Transport Systems 11/17/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Deal News, Licensing & Strategic Alliances, Life Sciences, Medical Devices.
Tags: , , , ,
add a comment

MBBP client, Paragonix Technologies Inc. recently entered into an exclusive distribution agreement with Pacific West Medical Sales to market Paragonix Technologies’ SherpaPakTM Cardiac and Kidney Transport Systems. The SherpaPakTM Cardiac and Kidney Transport Systems are innovative medical devices that are indicated for the static hypothermic preservation of donor hearts and kidneys during transportation and eventual transplantation into a recipient.

Pacific West Medical Sales is a medical equipment sales company that provides services for hospitals, doctors’ offices, and long-term care facilities, and provides supplies for emergency medical services and home medical needs. Paragonix Technologies, is a privately held medical device company founded in 2010 and is headquartered in Braintree, Massachusetts. For more information, read the full press release.

 

MBBP’s Client Continuum Adding Innovative Solutions To Policy Matters To Its Company Profile 11/16/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Corporate.
Tags: , , , , , , , , ,
add a comment

Continuum, a client of MBBP, has primarily focused on the design of innovative products since the company’s founding in 1983. However, the organization is now delving into policy matters within the public sector, including public school education and public service employment. Continuum has come forth with a “radical new vision” for the Boston Redevelopment Authority, the municipal planning and development agency for Boston public services. The company is offering fresh ideas in order to develop solutions to long-standing problems such as those within the Boston Public School districts, where the firm is working to “rethink the educational experience” in a project called High School Redesign.continuum-logo-m0371417xb1386

In addition to this educational reformation, Continuum has been shadowing public service workers and commuters, and asking a plethora of questions in order to improve public transportation. The firm has begun building and testing prototypes of devices that will prove integral in Continuum’s goal of improving the lives of the people of Boston.

Continuum is a global innovation design company whose purpose centers around people, as it strives to improve lives through its innovations and to focus on its clients’ bottom-lines. Read the full article for more information.

 

MBBP Client PMS Bites’ CEO Tania Green Recognized as Female Entrepreneur All Businesses Can Learn From 11/08/2016

Posted by Morse, Barnes-Brown Pendleton in Client News.
Tags: , , , , , ,
add a comment

Tania Green of firm client PMS Bites is recognized in the Living Business section of Colonial Life as 1 of 18 Bostonian female entrepreneurs from whom all businesses can learn.  The takeaway from Green’s mention is that any problem an individual may have, other individuals are also having, and therefore a solution would be useful to a wide audience. Green had a successful Kickstarter campaign for PMS Bites and was also featured on the hit show “Shark Tank”.logo

PMS Bites are edible chocolate snacks that are gluten free and vegan, and have all natural ingredients targeted toward combating female PMS symptoms.

Congratulations to Tania and PMS Bites!

Privacy & Data Security Video: Privacy & Data Security Issues for Service Recipients and Service Providers 11/01/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Intellectual Property, Privacy and Data Security.
Tags: , , , , , , , ,
add a comment

In our eighth and final Privacy & Data Security video clip, MBBP attorney Faith Kasparian discusses how companies sharing information with third-party service providers can create liabilities, both because many data breaches arise from third-party access, and because companies fail to oversee these third parties as required by law.  Faith will guide you through a few key points relevant to both service recipients and service providers.

Make sure to subscribe to our YouTube channel and to check out our Privacy & Data Security playlist for related videos.

fdkvideo8

MBBP Clients Red Crow and MiRTLE Medical Featured in Forbes Article Regarding New Equity Crowdfunding Platform 10/31/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Corporate, Financial Services, Life Sciences, Venture Capital & Private Equity.
Tags: , , , , , , , , , , , , ,
add a comment

MBBP clients Red Crow and MiRTLE Medical are featured in a Forbes article regarding Red Crow’s new equity crowdfunding portal that will be launching in November.  The crowdfunding platform will feature “exclusive and professionally-vetted investment opportunities” for accredited and non-accredited investors.

MiRTLE Medical will have one of the first featured investment opportunities. MiRTLE’s product is a custom designed diagnostic-grade 12-lead electrocardiogram for use during MRI.  MBBP is assisting MiRTLE Medical with its involvement in the crowdfunding platform.

To learn more, read the full Forbes article.

Firm Client MassDiGI Receives Federal Grant From U.S. Department of Commerce’s EDA 09/30/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Corporate, Games & Interactive Entertainment.
Tags: , , , , , , , ,
add a comment

MBBP client the Massachusetts Digital Games Institute (“MassDiGI”) at Becker College received a five-year grant in the amount of $583,000 from the U.S. Economic Development Administration, part of the U.S. Department of Commerce.  massdigi-logo-massdigixb1386The grant will support MassDiGI’s promotion of entrepreneurship, economic development, and academic cooperation across the state’s video and digital games ecosystem.

MassDiGI was established in 2011 and is based at Becker College.  Congratulations to our client on this impressive contribution.

MBBP Client HappyGiant Receives High Praise for New Video Game, Including from Rolling Stone 09/29/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Corporate, Games & Interactive Entertainment.
add a comment

Firm client HappyGiant, LLC is garnering a lot of attention for its new augmented reality and virtual reality game, HoloGrid: Monster Battles, including in an article in Rolling Stone.  For the new game, Michael Levine, president of HappyGiant, teamed up with Phil Tippett, who has designed countless movie monsters, including the ones featured in the famous 3-D chess scenes featured in the Star Wars franchise.

The virtual reality and augmented reality features of HoloGrid: Monster Battles create the effect of real life monster game pieces.  Levine and Tippett leveraged a successful Kickstarter campaign this year in order to create the game, described by VentureBeat as a “tactical-battle collectible card game”.  Tippett created the monster characters while HappyGiant focused on the creation of the Tactical Battle CCG augmented reality game.  The combination of the two designs resulted in a hybrid board/digital gaming experience.

MBBP is thrilled to have HappyGiant as a client and is excited to continue to work with them on their future endeavors.

You can find out more about HoloGrid: Monster Battles and HappyGiant in the following articles:

Rolling Stone
VentureBeat
Shacknews
UploadVR, Inc.

MBBP Client Koya Leadership Partners’ Founder & CEO Awarded 2016 Boston Brava Award 09/29/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Corporate, Venture Capital & Private Equity.
Tags: , , , , , , , , , ,
add a comment

Firm client Katie Bouton of Koya Leadership Partners received the 2016 Boston Brava Award from SmartCEO.  The Boston Brava Award recognizes high-impact female business leaders who are CEOs, Executive Directors of Nonprofits, or C-suite executives.  An independent committee of local business leaders chooses the winner of the Brava Award.  Winners are chosen for their commitment to giving back to their communities, and for their company’s growth, mentoring, and community impact.

Koya Leadership Partners was founded on the belief that “the right person in the right place can change the world”.  The company conducts executive searches and provides human capital consulting and career coaching services.

Congratulations to Katie and Koya Leadership Partners!

Firm Client TechSandBox Launches Veterans’ Technology Entrepreneurship Program 08/19/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Intellectual Property.
Tags: , , , , , , , , , , , , , , ,
add a comment

Morse, Barnes-Brown & Pendleton sponsored organization and client, TechSandBox, announced its partnership with MassDevelopment and the Massachusetts Technology Collaborative (“MassTech”) in the launch of a new program for military veterans.  The Military Veteran Entrepreneurs in Technology program (“VET”) is for veterans who are starting and growing new ventures in innovation-focused sectors and will provide support via mentoring, networking, and advising, among other services.  TechSandBox Logo (M0654842xB1386)

Through its involvement with VET, TechSandBox will supply veterans with the necessary resources to create and foster successful startups.  Specifically, TechSandBox will document the needs of the veterans, deliver programming for entrepreneurial development, and provide a network of other entrepreneurs in which the veterans can interact.

The VET will serve veterans in the MetroWest region and the Commonwealth.  The program will begin with a pilot phase, which will last for 18 months.  MassDevelopment and MassTech provided a combined grant of $53,101 for the pilot program.  For more information about the program, view TechSandBox’s website.

TechSandBox is a technology incubator for innovation-driven companies.  Its mission is to accelerate the success of science and technology entrepreneurs.  MBBP is proud of its client’s community-focused approach and the commitment to veterans through this new program.

Harvard Stem Cell Institute Teaming Up to Develop Diabetes Cure 08/18/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Intellectual Property, Medical Devices.
Tags: , , , , , , , , , ,
add a comment

A group of Boston-area health institutions, known as the Boston Autologous Islet Replacement Program, are teaming up to develop, test and deploy stem cells to cure diabetes. The group includes the Harvard Stem Cell Institute, Brigham and Women’s Hospital, the Joslin Diabetes Center, Dana-Farber Cancer Institute and Semma Therapeutics.

The innovation began when Doug Melton, Co-Director of Harvard Stem Cell Institute and Co-Founder of Semma Therapeutics, developed a way to turn embryonic stem cells into insulin-producing beta cells without needing to put the cells into mice to mature.  After this discovery, he knew he had to get these beta cells into humans but that it was going to take a group with the proper qualifications.

Melton explains, “No one institution anywhere has the expertise and technical abilities to make this kind of clinical trial possible, but in the unique Harvard biomedical ecosystem, we are able to bring all the necessary expertise and infrastructure to bear.” This new organization has the goal of testing the created beta cells in human patients within three years.

Congratulations to our client Harvard on these exciting new developments! For more information, read the full article.

Interview with MBBP Client Valeritas Included in Wall Street Transcript Medical Devices Report 08/09/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Intellectual Property, Life Sciences, Medical Devices.
Tags: , , , , , , , , , , , ,
add a comment

The most recent Wall Street Transcript Medical Devices Report includes an interview with Valeritas, Inc.’s CEO, John Timberlake.  Timberlake discusses in detail Valeritas’s V-Go Disposable Insulin Delivery Device. The V-Go is a wearable basal-bolus insulin delivery device that allows patients to deliver insulin at a continuous preset basal rate, with bolus delivery as needed.  The V-Go has been cleared for use in the United States and in Europe.  big valThe fact that V-Go is a wearable product with scheduled insulin delivery enables patients to more easily go about their daily routines without having to stop to deliver insulin, and also allows them to discreetly deliver insulin during mealtimes without drawing attention to the act.

Valeritas is a commercial-stage medical technology company that develops new Type II diabetes technology products aimed at improving the lives of patients with Type II diabetes.  For more information about Valeritas and its V-Go product, read the full interview with The Wall Street Transcript.

Firm Client Applied BioMath Recognized in Greater Boston’s 2016 Small Business of the Year Awards 08/02/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Corporate, Life Sciences.
Tags: , , , , , , , ,
add a comment

MBBP is thrilled to announce that client Applied BioMath, LLC is one of ten winners of the 2016 Small Business of the Year Awards (SBOY), announced by The Greater Boston Chamber of Commerce.  The SBOY recognizes smaller for-profit companies within the Greater Boston area who possess product innovation, workplace excellence, community and social responsibility, strong financial performance, and achievement in management.Applied BioMath Logo (M0887167xB1386)

Applied BioMath, LLC was founded in 2013 with the goal of transforming the quality and the economics of drug invention by applying advanced mathematical analysis at critical decision points in the drug invention process.  The ten award winners will be recognized at the event “Nailed It: A Conversation with Successful Business Leaders”, which will be held on October 6th.

MBBP assisted Applied BioMath in drafting its various Service Agreements with customers, among other key legal services.  Congratulations to our client in what is sure to be one of many successes!

MBBP Client Fanzcall Receives Backing from Red Sox’s David Ortiz 07/29/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Corporate, Games & Interactive Entertainment.
Tags: , , , , , , , ,
add a comment

logoFanzcall, an interactive live sports game app, announced that Boston Red Sox’s David Ortiz is now a shareholder in the Waltham-based startup company.  Ortiz has an equity stake in the company, and will serve as an Ambassador.  Fanzcall allows users to guess the outcome of at-bats during live games.  It was founded by Anton Khinchuk and has already raised approximately $1.6 million through investors.

Regarding his involvement with Fanzcall, Ortiz remarked “I’m excited that the Fanzcall app allows baseball fans to become a part of the game they love… I love this opportunity to work with Fanzcall to extend my own love of the game, even after I retire.”  The app is available for free in the App Store and in Google Play.

MBBP is thrilled to continue its work with client Fanzcall, and looks forward to witnessing its continued success!

Client Alert: EU-U.S. Privacy Shield Adopted 07/15/2016

Posted by Morse, Barnes-Brown Pendleton in Client News.
add a comment

The European Commission Has Adopted and Launched
the EU-U.S. Privacy Shield 

By: Faith Kasparian

client alert skinnyEarlier this week, the European Commission adopted the EU-U.S. Privacy Shield – a new framework for transatlantic data flows.  The European Commission’s Press Release announcing the Shield promises that the new framework “protects the fundamental rights of anyone in the EU whose personal data is transferred to the United States” and brings “legal clarity for businesses relying on transatlantic data transfers.”

The EU-U.S. Privacy Shield replaces the Safe Harbor framework, which previously governed data transfers between the EU and the U.S. until it was declared invalid by the Court of Justice of the European Union on October 6, 2015.  On February 2, 2016, the EU and the U.S. reached political agreement as to the new Privacy Shield.  The European Commission’s “adequacy decision” implementing the Privacy Shield was approved on July 12.  See our prior Alerts on this subject here and here.

Read the full alert which includes the principal elements of the Privacy Shield.

MBBP’s Life Sciences Vector, Summer 2016 07/14/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Life Sciences, MBBP news, New Resources.
Tags: , , ,
add a comment

ext2016 LIFE SCIENCES PANEL SERIES

At the second of our Life Sciences panel Series: “Laying the Foundation for Growth: Entity & Equity”, experts discussed whether a corporation or a limited liability company is the “Right Stuff ” for building an emerging company, and how to structure and optimize the equity compensation of the team. MBBP’s John Hession moderated the panel, which included Marc Cote of Accellient and Jeff Solomon of Katz Nannis + Solomon. Stay tuned for details on Panel 3 in the fall.

Click here to learn more.

MBBP ADDS TWO ATTORNEYS

Weatherly Ralph Emans, Corporate Senior Attorney – As a member of the firm’s PIFA team in the corporate group, Weatherly focuses her practice primarily on private investment funds, including private equity funds, venture funds, hedge funds and funds of funds. Weatherly’s practice also includes venture capital transactions and providing general corporate advice to early stage companies.

Amanda R. Phillips, Litigation Associate – As a member of the firm’s litigation practice, Amanda focuses her practice on commercial civil disputes and securities litigation, and has broad experience working with clients under investigation by federal and state government agencies.

WAIT A MINUTE MR. POSTMAN…

Sooner or later many companies with a successful product or service will receive an overture from a patent holder. Some are almost friendly, proposing a potential mutually beneficial business relationship involving the patent. Others are decidedly less so, leveling claims of patent infringement and seeking immediate termination of the activity or product sales and/or significant financial compensation. This entire range of written communications is commonly referred to as “demand letters.” So – what’s the next step if your company receives a demand letter?

Read more on Page 2.

SUPREME COURT DENIES SEQUENOM’ PETITION TO CLARIFY SCOPE OF MAYO IN SEQUENOM V. ARIOSA

On June 27, 2016, the United States Supreme Court denied a Petition for Writ of Certiorari filed by Sequenom, Inc. requesting the Supreme Court to clarify the scope of its Mayo Collaborative Services v. Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012) decision, as applied to Sequenom’s claimed inventions. The Mayo decision, which held that a method correlating a drug dosage regimen and levels of the drug in the blood was an unpatentable law of nature, has had the profound effect of narrowing the scope of patent-eligible subject matter in the United States and has cast doubt on the validity and enforceability of previously issued United States patents.

Read more on Page 3.

CLIENT SPOTLIGHT: iSpecimen 

iSpecimen is a trusted, one-stop source of customized human biospecimen collections. Compliantly sourced from our diverse
partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations, our solid tissues, biofluids, and cells are delivered directly into the hands of biomedical researchers using our unique, turnkey technology. Scientists gain access to a ready supply of the high-quality, richly-annotated specimens they need from the patients they want. Supply partners gain an opportunity to further contribute to biomedical discovery as well as their bottom line.

Read more on Page 4.

Client Corista Selected by Johns Hopkins Medicine to Extend Pathology Capabilities 07/11/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Medical Devices.
Tags: , , ,
add a comment

Corista Logo (M0931457xB1386)Exciting news for MBBP client Corista as Johns Hopkins Medicine, one of the leading health care systems in the United States, has successfully installed Corista’s DP3 system. The DP3 is a digital pathology network platform that removes the physical boundaries from pathology and enables real-time remote expert diagnoses. It is a workflow solution integrating multiple facilities, scanners, physicians, patients and Laboratory Information Systems.

Johns Hopkins is standardizing this DP3 system as its centralized digital pathology platform in order to streamline workflows among its five hospital centers. The overall objective is to provide more efficient and accurate flow of information across core systems that manage diverse functions in the hospital system. Specifically, the system will help improve each hospital’s Tumor Board process, integration of existing systems including LIS, and global remote access.

Congratulations, Corista! MBBP serves as general counsel to Corista and assisted in negotiating its contract with Johns Hopkins. For more information, visit Corista News & Events.

MBBP Client BBK Worldwide Partners with Apptomics on App to Monitor Parkinson’s Patients 07/11/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Computer Software & Hardware, Life Sciences, Medical Devices.
Tags: , , , , , , , , ,
add a comment

Firm client BBK Worldwide is partnering with Wellesley-based digital health app maker, Apptomics, as it prepares to launch a one-year clinical trial in September. Using a combination of apps (iMotor and MyPD), for monitoring patients with Parkinson’s disease, the trial will test the effectiveness of these tools in impacting the management of Parkinson’s disease and health outcomes.  iMotor measures objectively patients’ motor function by combining several variables and MyPD focuses on collecting data related to symptoms, medications, side effects sleep quality, and emotional status. Data collected are transmitted in reports to patients’ neurologists.BBK Worldwide Holdings logo (M0790340xB1386)

BBK Worldwide is the foremost patient recruitment and engagement technology firm, providing a range of award-winning creative services and technology solutions to the world’s most innovative pharmaceutical and biopharmaceutical companies and their outsourced suppliers, such as CROs and eClinical providers. Apptomics works to achieve optimal management of chronic neurological conditions, including Parkinson’s, through scientifically validated mobile applications that allow collection of objective and patient reported data on disease progression.  BBK Worldwide is now a minority investor in Apptomics, with BBK Principal Matthew Stumm serving on the Apptomics Board of Directors.

The two companies will work to develop a collection of apps aimed at monitoring patients with chronic neurological diseases and relaying the information to their doctors.  Apptomics has already had success with the iMotor app through two studies that clearly demonstrated the scientific effectiveness of its data collection.  The app also proved able to distinguish Parkinson’s patients from healthy individuals, and distinguished with high sensitivity the effects of treatment plans.

Congratulations to both companies on their new venture!

 

MBBP Client ConforMIS, Inc. Acknowledged for Patient Satisfaction with Knee Replacements 07/07/2016

Posted by Morse, Barnes-Brown Pendleton in Client News, Employment, Life Sciences, Medical Devices.
Tags: , , , , , ,
add a comment

ConforMIS, Inc., a medical technology company that manufactures and sells joint replacement implants, received positive results from its iTotal CR study.  The iTotal CR is a fully customized implant for use in total knee replacement, and the study found that 92% of patients were satisfied with the product in the year after receiving a knee replacement.  conformis-inc-logo

In developing, manufacturing, and selling joint replacement implants, ConforMIS uses its iFit Image-to-Implant technology, which allows for a customized implant specifically designed to fit an individual’s anatomy.  The iTotal CR study included 300 patients in the United States, and is still ongoing.  The interim study results were presented at the 2016 SICOT International Orthopaedic “Specialized Knee Surgery” Conference in Germany, which ran from June 30th to July 2nd.

The positive feedback is consistent with a previous study that showed that patients noted significantly higher satisfaction with the ConforMIS iTotal CR in their knee replacements, than with off-the-shelf implants.  The positive results speak to the benefits of anatomically customized implants, and illustrate how ConforMIS’s products are making a positive and lasting impact in the joint replacement implant market.

To read more about the study and ConforMIS’s technology, read the full article.

%d bloggers like this: